CA2847197C - Treatment for dupuytren's disease - Google Patents

Treatment for dupuytren's disease Download PDF

Info

Publication number
CA2847197C
CA2847197C CA2847197A CA2847197A CA2847197C CA 2847197 C CA2847197 C CA 2847197C CA 2847197 A CA2847197 A CA 2847197A CA 2847197 A CA2847197 A CA 2847197A CA 2847197 C CA2847197 C CA 2847197C
Authority
CA
Canada
Prior art keywords
disease
tnf
antagonist
dupuytren
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2847197A
Other languages
English (en)
French (fr)
Other versions
CA2847197A1 (en
Inventor
Jagdeep Nanchahal
Kim Suzanne Midwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1018325.9A external-priority patent/GB201018325D0/en
Priority claimed from GBGB1018362.2A external-priority patent/GB201018362D0/en
Priority claimed from GBGB1113718.9A external-priority patent/GB201113718D0/en
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Publication of CA2847197A1 publication Critical patent/CA2847197A1/en
Application granted granted Critical
Publication of CA2847197C publication Critical patent/CA2847197C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CA2847197A 2010-10-30 2011-10-31 Treatment for dupuytren's disease Active CA2847197C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB1018325.9 2010-10-30
GBGB1018325.9A GB201018325D0 (en) 2010-10-30 2010-10-30 Treatment for dupuytren's disease
GB1018362.2 2010-11-01
GBGB1018362.2A GB201018362D0 (en) 2010-11-01 2010-11-01 Treatment of dupuytren's disease
GB1113718.9 2011-08-10
GBGB1113718.9A GB201113718D0 (en) 2011-08-10 2011-08-10 Treatment of Dupuytren's Disease
PCT/EP2011/069147 WO2012056044A1 (en) 2010-10-30 2011-10-31 Treatment for dupuytren's disease

Publications (2)

Publication Number Publication Date
CA2847197A1 CA2847197A1 (en) 2012-05-03
CA2847197C true CA2847197C (en) 2020-11-03

Family

ID=44913268

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2847197A Active CA2847197C (en) 2010-10-30 2011-10-31 Treatment for dupuytren's disease

Country Status (9)

Country Link
US (3) US9138458B2 (https=)
EP (1) EP2632446B1 (https=)
JP (2) JP6004494B2 (https=)
AU (2) AU2011322482B2 (https=)
CA (1) CA2847197C (https=)
DK (1) DK2632446T3 (https=)
ES (1) ES2715204T3 (https=)
RU (1) RU2013123796A (https=)
WO (1) WO2012056044A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013123796A (ru) 2010-10-30 2014-12-10 Исис Инновэйшн Лтд Способ лечения болезни дюпюитрена
EP2844276B1 (en) 2012-05-01 2019-10-02 Proteolease Ltd. Methods for extracting a tooth
US20130297023A1 (en) * 2012-05-07 2013-11-07 Hee-Jeong Im Sampen Methods and Devices For Treating Intervertebral Disc Disease
US20160158325A1 (en) * 2013-07-11 2016-06-09 180 Therapeutics Lp Method of treating fibroproliferative disorders including dupuytren's disease with one or more specific human matrix metalloproteinase and a tnf antagonist
EP3265493B1 (en) 2015-03-02 2024-01-10 180 Therapeutics LP Method of treating a localized fibrotic disorder using an il-33 antagonist
EP3439701A4 (en) * 2016-04-08 2019-12-11 180 Therapeutics LP METHOD FOR THE TREATMENT OF DUPUYTRIAL DISEASE IN EARLY STAGE
EP3570865A4 (en) * 2016-09-02 2020-05-20 180 Therapeutics LP METHOD FOR TREATING A LOCALIZED FIBROTIC DISEASE USING A BISPECIFIC IL-33 / TNF ANTIBODY
EP3506920A4 (en) * 2016-09-02 2020-05-27 180 Therapeutics LP METHOD FOR TREATING SYSTEMIC FIBROTIC DISEASES WITH A BISPECIFIC IL-33 / TNF ANTIBODY
US11564963B2 (en) 2017-11-22 2023-01-31 Progeneron, Llc Topical compositions, process of large-scale manufacture, and method of use
WO2020247808A1 (en) 2019-06-07 2020-12-10 Dale Biotech, Llc Method for treating dupuytren's disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0939121B2 (de) * 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
GB9405076D0 (en) * 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors
US6486140B2 (en) * 1994-07-19 2002-11-26 Medicarb Ab Agents, and methods employing them, for the prevention or reduction of tissue adhesion at a wound site
US5589171A (en) 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CN1083337C (zh) 1996-03-26 2002-04-24 精工爱普生株式会社 打印装置及其控制方法
US6086872A (en) 1997-03-27 2000-07-11 Advance Biofactures Of Curacao, Nv Amelioration of dupuytren's disease
US6031005A (en) * 1998-08-03 2000-02-29 Easterling; W. Jerry Composition and method for treating Peyronie's disease and related connective tissue disorders
US6060474A (en) * 1998-11-05 2000-05-09 New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method for preventing scar tissue formation
GB0105330D0 (en) 2001-03-02 2001-04-18 Renovo Ltd Genetic testing
US7754217B2 (en) * 2001-03-16 2010-07-13 Bio3 Research Srl HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
EP1385516A1 (en) * 2001-04-30 2004-02-04 Arachnova Therapeutics Ltd. The treatment of scarring and related conditions using ppar-gamma activators
US7553488B2 (en) 2002-07-05 2009-06-30 UNIVERSITé LAVAL Antibodies against S100A8 and S100A9 proteins for modulating inflammatory reactions
GB0306165D0 (en) 2003-03-18 2003-04-23 Delta G Ltd Medical treatment
WO2005000227A2 (en) * 2003-06-06 2005-01-06 Intermune, Inc. Methods of treating tnf-mediated disorders
WO2005074913A2 (en) 2004-01-30 2005-08-18 Angiotech International Ag Compositions and methods for treating contracture
AU2006206393B2 (en) * 2005-01-21 2010-04-08 The Research Foundation Of State University Of New York Methods for treating adhesive capsulitis
US7431927B2 (en) * 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
WO2010102202A2 (en) 2009-03-06 2010-09-10 Kenneth William Gregg Composition for controlling fish
EP2403523A1 (en) 2009-03-06 2012-01-11 Halozyme, Inc. Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof
RU2013123796A (ru) 2010-10-30 2014-12-10 Исис Инновэйшн Лтд Способ лечения болезни дюпюитрена

Also Published As

Publication number Publication date
US10273296B2 (en) 2019-04-30
EP2632446B1 (en) 2018-12-12
CA2847197A1 (en) 2012-05-03
US20190322733A1 (en) 2019-10-24
JP6004494B2 (ja) 2016-10-12
AU2017204267A1 (en) 2017-07-13
US9138458B2 (en) 2015-09-22
ES2715204T3 (es) 2019-06-03
AU2017204267B2 (en) 2019-05-23
AU2011322482A1 (en) 2013-05-23
JP2013540803A (ja) 2013-11-07
JP2017014266A (ja) 2017-01-19
EP2632446A1 (en) 2013-09-04
RU2013123796A (ru) 2014-12-10
US10669334B2 (en) 2020-06-02
AU2011322482B2 (en) 2017-03-23
US20130287760A1 (en) 2013-10-31
US20160280775A1 (en) 2016-09-29
WO2012056044A1 (en) 2012-05-03
DK2632446T3 (en) 2019-04-01

Similar Documents

Publication Publication Date Title
US10669334B2 (en) Treatment for Dupuytren's disease
Armour et al. Cellular and molecular pathology of HTS: basis for treatment
US10858449B1 (en) Methods and compositions for treating osteoarthritis
JP7558900B2 (ja) 化膿性汗腺炎の治療に使用するための抗ｃｄ４０抗体
KR101397912B1 (ko) 여드름 및 기타 질환 치료용 비스파틴 치료제
US10961321B1 (en) Methods and compositions for treating pain associated with inflammation
CN101146547A (zh) 肌肉生长抑制素（gdf-8）拮抗剂用于增进创伤愈合和防止纤维变性疾病的用途
Huang et al. Pharmacological treatment for keloids
US10995151B1 (en) Methods and compositions for treating disease-related cachexia
US20240000930A1 (en) Methods and compositions for treating kidney diseases
KR20170082631A (ko) 뇌졸중의 치료 또는 예방 방법
Zheng et al. C5a/C5aR1 mediates IMQ‐induced psoriasiform skin inflammation by promoting IL‐17A production from γδ‐T cells
KR20190014454A (ko) Crif1 억제제를 함유하는 켈로이드 및 비후성 반흔 형성 억제 또는 치료용 조성물
WO2012033518A1 (en) Methods and compositions for treating metabolic disorders
KR102206017B1 (ko) Parp1 저해제를 포함하는 피부 섬유화 질환 치료용 약학적 조성물
WO2013064585A1 (en) Treatment of musculoskeletal fibroproliferative disorders
Nanchahal et al. Treatment for dupuytren's disease
US12221463B2 (en) Method of promoting wound healing by inhibiting CCR3
JP2022500387A (ja) Ｍｕｓｋ阻害
CN121003696A (zh) 一种靶向b细胞和软骨细胞衰老的骨关节炎治疗药物
EP4308231A1 (en) Wound healing enhancement with anti-ceramide antibodies
US20200062855A1 (en) Compositions and methods of promoting wound healing
Saraceno et al. Recent patents and new strategies in the treatment of psoriasis
WO2021022228A1 (en) Methods and compositions for treating and preventing damage to skin
Armour et al. Cellular and molecular pathology of HTS: basis for treatment [corrected][published erratum appears in WOUND REPAIR REGENERATION 2008 Jul-Aug; 16 (4): 582].

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20161013

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241030

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241030

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241030

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251217

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260319

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260319